Patrick A emails, "Please blast Spectrum Pharmaceuticals'(SPPI - Get Report) CEO, Raj Shrotriya. Please. I am a shareholder but I am absolutely sickened by the amount of compensation this guy receives. Yes, the stock has had a nice run, but assuming Shrotriya gets his 520,000-share award this month, the total amount of shares awarded to Shrotriya in 2011 will be 2.87 million shares. Yes, 2.87 million shares in either awards or options in a single calendar year! This in addition to a $1.9 million cash bonus! Am I wrong in considering this absolutely ridiculous? I am pissed off as a shareholder. The dude pays himself like he's running a multibillion-dollar large pharma with thousands of employees bringing in billions of revenue. Spectrum is a $800 million [market value] company with 150 employees. His compensation is ridiculous." Well said. Shrotriya's compensation is obscene. He had a good year, no doubt. I even nominated him for the Best Biotech CEO of 2011 award. But Patrick is right, Spectrum's board pays Shrotriya as if he's running a highly profitable, large-cap biotech company. He's not.
John Paul writes, "I really don't know who the worst biotech CEO should be, but I pronounce you the winner in the homer [sic] Simpson lookalike contest." Doh! --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.